Organ Meats / Nose-to-Tail Nutrient Density

Overview

This episode of The Breastcancer.org Podcast features Chelsea Vangrol, a medical assistant diagnosed with ductal carcinoma in situ (DCIS) breast cancer at age 25. Chelsea shares her journey from diagnosis through treatment and survivorship, highlighting the emotional impact, decision-making process, and challenges faced by young adults with breast cancer.

Diagnosis and Genetic Testing

Chelsea was diagnosed after a mammogram revealed suspicious calcifications in her right breast. She had undergone genetic testing due to family history, testing positive for the BRIP-1 gene mutation, which is more commonly associated with ovarian cancer but has uncertain links to breast cancer. Despite her young age and lack of a first-degree relative with breast cancer, she was able to access imaging through her workplace at a breast imaging center. The mammogram and subsequent biopsy confirmed DCIS, a stage zero breast cancer.

Treatment Decisions

After diagnosis, Chelsea underwent an MRI and consulted with a breast surgeon who presented treatment options without pressure. These included lumpectomy with possible radiation and hormone therapy or a double mastectomy to avoid radiation and hormone blockers. Chelsea chose a double mastectomy for peace of mind, influenced by her aunt's history of invasive breast cancer and recurrence despite prior surgery. She also had reconstructive surgery. Chelsea notes that the decision was complex, involving considerations about fertility, body image, and long-term health.

Fertility and Hormonal Concerns

Chelsea did not initially see an oncologist and thus fertility preservation was not discussed at diagnosis. She later sought oncological advice regarding hormonal birth control to regulate menstrual cycles but has ongoing concerns about pregnancy and cancer recurrence risk given her gene mutation and cancer history. She acknowledges unanswered questions about fertility and future family planning.

Emotional and Practical Challenges

Chelsea describes the emotional shock of diagnosis, the difficulty of sharing the news with loved ones, and the ongoing adjustment to life after surgery. She emphasizes the importance of a strong support system, including family, coworkers, and medical staff. Chelsea also discusses survivor's guilt common among those with DCIS, as well as the challenges of body image changes and weight gain related to treatment and stress.

Unique Issues for Young Adults

Chelsea highlights the difficulties young women face in obtaining appropriate breast imaging due to age-based guidelines and insurance coverage limitations. She stresses the importance of self-advocacy and awareness, noting that breast cancer can occur in younger people and may be missed without mammograms since some abnormalities like calcifications are not visible on ultrasound. Chelsea encourages young patients to seek imaging if they notice changes and to connect with communities for support.

Advice and Support for Others

Chelsea encourages others diagnosed in their 20s to find community and support networks, including online groups and resources like Breastcancer.org. She stresses the importance of advocating for oneself and trusting one’s instincts when navigating diagnosis and treatment. Chelsea’s story aims to reduce isolation and fear for young adults facing breast cancer.

Source Information

This content is based on a 25-minute podcast episode from The Breastcancer.org Podcast titled "Chelsea’s Story: Diagnosed With Breast Cancer at 25," hosted by Jamie DePolo. The episode features a personal interview with Chelsea Vangrol, who shares her firsthand experience with breast cancer diagnosis, treatment, and survivorship as a young adult. The transcript was used to provide detailed insights into her story and perspectives. The podcast is intended to inform and support people affected by breast cancer, emphasizing patient experience and practical decision-making without providing medical advice.

This Cancer Advances episode discusses the Cleveland Clinic Cellular and Immunotherapy Service and the growing use of immune effector cell therapies such as CAR-T therapy and bispecific antibodies. It is especially useful for understanding how hospitals organize care around complex immunotherapy treatments and side effects.